Last Updated: 13 Nov 2024
Executive Summary
Ardent Health Partners, Inc. (ARDT) is a leading healthcare provider with a market capitalization of $2.59 billion. The company has a strong financial position with an EBITDA of $412.14 million and a profit margin of 1.54%. ARDT's recent financial performance has been positive, with a quarterly earnings growth of 29.3% and a quarterly revenue growth of 7.5%. The company has a forward PE ratio of 9.55 and a price-to-sales ratio of 0.46, indicating that it is undervalued compared to its peers.
Company Overview
Ardent Health Partners is a healthcare provider that operates 30 hospitals and over 200 clinics in seven states. The company provides a wide range of services, including acute care, behavioral health, and surgical care. ARDT has a strong focus on quality and patient satisfaction, and it has been recognized for its high levels of patient care.
Fundamental Analysis
ARDT's financial position is strong, with a debt-to-equity ratio of 0.52 and a current ratio of 1.23. The company has a history of profitability, with a net income margin of 1.54% in the past year. ARDT's revenue has grown by 7.5% in the past year, and the company is expected to continue to grow in the future.
Technical Analysis
ARDT's stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages, and it has formed a bullish pennant pattern. This pattern indicates that the stock is likely to continue to rise in the short term.
Short Term Outlook
ARDT's stock price is expected to continue to rise in the short term. The stock is currently trading at $17.14, and it is expected to reach $20 by the end of the year.
Long Term Outlook
ARDT is a well-positioned company with a strong financial position and a history of growth. The company is expected to continue to grow in the long term, and its stock price is expected to appreciate accordingly.
Analyst Recommendations
Four analysts have a strong buy rating on ARDT, five have a buy rating, and one has a hold rating. The average analyst target price is $22.78.
